Efficacy
Proven efficacy in IVF/ICSI clinical trial
In a randomized, double-blind, active-controlled study, healthy, normal ovulatory women were treated for 1 cycle of controlled ovarian stimulation with FOLLISTIM AQ Cartridge in a gonadotropin-releasing hormone (GnRH) antagonist protocol as part of an IVH or ICSI program. Clinical pregnancy was assessed ≥6 weeks after transfer of 1 or 2 embryos. No luteinizing-hormone (LH) supplementation used.1
- North American clinical pregnancy rate of 48.9% (n=403).
- Overall clinical pregnancy rate in the FOLLISTIM AQ Cartridge group of 41.1% (n=750).
Study treatment protocol1

(a) Dosage adjustments of FOLLISTIM AQ Cartridge could be considered from the 6th day of treatment onward according to individual response.1
Study design
The ENGAGE trial was a single-cycle, randomized, double-blind, active-controlled trial. Clinical pregnancy was assessed ≥6 weeks after transfer of 1 or 2 embryos. The study included 1,509 IVF patients in 34 centers in Europe, Canada, and the United States. 750 patients were treated with FOLLISTIM AQ Cartridge—approximately 54% of patients (n=403) treated at 14 study sites in North America. Patients were treated for 1 cycle of controlled ovarian stimulation with FOLLISTIM AQ Cartridge in a gonadotropin-releasing hormone (GnRH) antagonist protocol as part of an IVF or ICSI program. No luteinizing-hormone (LH) supplementation was used.1
Reference
1. Devroey P, Boostanfar R, Koper NP, et al; BCJM; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24(12):3063-3072.